# Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents

> **NCT00412503** · PHASE1 · COMPLETED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris**

## Conditions studied

- Refractory Tumors
- Malignant Tumors

## Interventions

- **DRUG:** Topotecan, Temozolomide

## Key facts

- **NCT ID:** NCT00412503
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2009-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00412503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00412503, "Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00412503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*